Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GGT1 | P19440 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6665890 | 0.82 | PTGS2 (0.52) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL2797501 | 0.81 | ALDH1A1 (0.53) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL16623989 | 0.81 | PTGS2 (0.50) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL9263634 | 0.79 | PTGS2 (0.49) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL7121792 | 0.79 | PTGS2 (0.49) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL65021 | 0.79 | IDO1 (0.58) | KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL68677 | 0.78 | PTGS2 (0.55) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL30850062 | 0.78 | PTGS2 (0.55) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL11589528 | 0.78 | PTGS2 (0.55) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL10924111 | 0.77 | PTGS2 (0.53) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265849-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9676703-B2 | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20160200690-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-07-14 | — | — | US | disclosed |
| EP-3031802-A1 | PRODUCTION METHOD FOR 3, 3-DIMETHYL-3, 4-DIHYDRO-1H-QUINOXALINE-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | Santen Pharmaceutical Co., Ltd (JP) | 2016-06-15 | — | — | EP | disclosed |
| EP-2282753-A1 | ASSAY FOR PATHOGENIC CONFORMERS | Novartis AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-2146632-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | The Board of Regents of The University of Texas System (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009134942-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG. (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2008130439-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007047305-A1 | METHODS OF TREATING AMYLOIDOSIS USING CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| EP-1265849-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | CBR3, NOS3, CBR1 | PTGS2 364/4885KDM4E 1362/4885HSD17B10 330/4885 |
| US-20160200690-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | CBR3, NOS3, CBR1 | PTGS2 361/4885KDM4E 1301/4885HSD17B10 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.